ZyversaREV_cmyk.jpg
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
July 09, 2024 07:57 ET | ZyVersa Therapeutics
ZyVersa welcomes one-on-one meetings at the HCW Kidney Conference on July 15, 2024.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
May 15, 2024 08:35 ET | ZyVersa Therapeutics
ZyVersa is on track to achieve key development milestones over the next 3 quarters.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
May 14, 2024 07:57 ET | ZyVersa Therapeutics
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 25, 2024 08:17 ET | ZyVersa Therapeutics
Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical program...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
March 18, 2024 07:57 ET | ZyVersa Therapeutics
Initiation of Phase 2a trial first half 2024 with Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease is a key milestone for ZyVersa.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
January 10, 2024 08:06 ET | ZyVersa Therapeutics
View ZyVersa Therapeutics' Benzinga All Access Interview To Learn About Key Development Milestones in 2024.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
January 04, 2024 07:50 ET | ZyVersa Therapeutics
ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
January 03, 2024 08:07 ET | ZyVersa Therapeutics
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
December 18, 2023 08:12 ET | ZyVersa Therapeutics
WESTON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
December 14, 2023 07:01 ET | ZyVersa Therapeutics
ZyVersa engages CRO, George Clinical, to manage its P2a clinical trial with VAR 200 in Diabetic Kidney Disease expected to begin Q1-2024.